Evaluation Of Renal Safety Of Raas Inhibitor Therapy: A Clinical And Pharmacovigilant Study

After initiating a renin-angiotensin-aldosterone system (raas) inhibitor, there is a risk of decreased renal functions or hyperkalaemia. Hence, biochemical monitoring tests for serum creatinine and potassium are warranted after therapy initiation and are mandatory by guidelines. However, adherenc...

Full description

Bibliographic Details
Main Author: Khaleel, Mohammad Ali Mohammad
Format: Thesis
Language:English
Published: 2024
Subjects:
Online Access:http://eprints.usm.my/62705/
http://eprints.usm.my/62705/1/24%20Pages%20from%20MOHAMMAD%20ALI%20MOHAMMAD%20KHALEEL.pdf
_version_ 1848885066249273344
author Khaleel, Mohammad Ali Mohammad
author_facet Khaleel, Mohammad Ali Mohammad
author_sort Khaleel, Mohammad Ali Mohammad
building USM Institutional Repository
collection Online Access
description After initiating a renin-angiotensin-aldosterone system (raas) inhibitor, there is a risk of decreased renal functions or hyperkalaemia. Hence, biochemical monitoring tests for serum creatinine and potassium are warranted after therapy initiation and are mandatory by guidelines. However, adherence to the guidelines for performing these monitoring tests has been reported to be low globally, with unknown rates in malaysia. Additionally, the prevalence of serum creatinine increase by ≥30% or hyperkalaemia in malaysia after initiating raas inhibitors remains unknown. Using data from hospital universiti sains malaysia (husm) from 2010 to 2020, we studied serum creatinine increase and hyperkalaemia prevalence, along with this monitoring tests adherence. Adherence within 15 and 60 days of raas inhibitor initiation was 6.7% and 20.3%, respectively. Incidence rates of serum creatinine increase within 15 and 60 days were 4.9% and 6.7%, and for hyperkalaemia, 1.6% and 1.9%, respectively. An ensembled machine learning algorithm was developed using husm data to predict a ≥30% increase in serum creatinine within 60 days, showing robust performance metrics (auc: 0.945, accuracy: 0.959, precision: 0.737, sensitivity: 0.583, specificity: 0.985, balanced accuracy: 0.784). The predictive model would help physicians to easily highlight patients at high risk, make sure those patients will not miss the monitoring tests, and give physicians a chance to be proactive with patients’ treatment plans rather than reactive. For a more comprehensive study, we utilized the fda adverse event reporting system (faers), one of the world's largest pharmacovigilance databases, covering data from january 2004 to september 2021.
first_indexed 2025-11-15T19:16:41Z
format Thesis
id usm-62705
institution Universiti Sains Malaysia
institution_category Local University
language English
last_indexed 2025-11-15T19:16:41Z
publishDate 2024
recordtype eprints
repository_type Digital Repository
spelling usm-627052025-07-29T01:23:34Z http://eprints.usm.my/62705/ Evaluation Of Renal Safety Of Raas Inhibitor Therapy: A Clinical And Pharmacovigilant Study Khaleel, Mohammad Ali Mohammad RS1-441 Pharmacy and materia medica After initiating a renin-angiotensin-aldosterone system (raas) inhibitor, there is a risk of decreased renal functions or hyperkalaemia. Hence, biochemical monitoring tests for serum creatinine and potassium are warranted after therapy initiation and are mandatory by guidelines. However, adherence to the guidelines for performing these monitoring tests has been reported to be low globally, with unknown rates in malaysia. Additionally, the prevalence of serum creatinine increase by ≥30% or hyperkalaemia in malaysia after initiating raas inhibitors remains unknown. Using data from hospital universiti sains malaysia (husm) from 2010 to 2020, we studied serum creatinine increase and hyperkalaemia prevalence, along with this monitoring tests adherence. Adherence within 15 and 60 days of raas inhibitor initiation was 6.7% and 20.3%, respectively. Incidence rates of serum creatinine increase within 15 and 60 days were 4.9% and 6.7%, and for hyperkalaemia, 1.6% and 1.9%, respectively. An ensembled machine learning algorithm was developed using husm data to predict a ≥30% increase in serum creatinine within 60 days, showing robust performance metrics (auc: 0.945, accuracy: 0.959, precision: 0.737, sensitivity: 0.583, specificity: 0.985, balanced accuracy: 0.784). The predictive model would help physicians to easily highlight patients at high risk, make sure those patients will not miss the monitoring tests, and give physicians a chance to be proactive with patients’ treatment plans rather than reactive. For a more comprehensive study, we utilized the fda adverse event reporting system (faers), one of the world's largest pharmacovigilance databases, covering data from january 2004 to september 2021. 2024-07 Thesis NonPeerReviewed application/pdf en http://eprints.usm.my/62705/1/24%20Pages%20from%20MOHAMMAD%20ALI%20MOHAMMAD%20KHALEEL.pdf Khaleel, Mohammad Ali Mohammad (2024) Evaluation Of Renal Safety Of Raas Inhibitor Therapy: A Clinical And Pharmacovigilant Study. PhD thesis, Perpustakaan Hamzah Sendut.
spellingShingle RS1-441 Pharmacy and materia medica
Khaleel, Mohammad Ali Mohammad
Evaluation Of Renal Safety Of Raas Inhibitor Therapy: A Clinical And Pharmacovigilant Study
title Evaluation Of Renal Safety Of Raas Inhibitor Therapy: A Clinical And Pharmacovigilant Study
title_full Evaluation Of Renal Safety Of Raas Inhibitor Therapy: A Clinical And Pharmacovigilant Study
title_fullStr Evaluation Of Renal Safety Of Raas Inhibitor Therapy: A Clinical And Pharmacovigilant Study
title_full_unstemmed Evaluation Of Renal Safety Of Raas Inhibitor Therapy: A Clinical And Pharmacovigilant Study
title_short Evaluation Of Renal Safety Of Raas Inhibitor Therapy: A Clinical And Pharmacovigilant Study
title_sort evaluation of renal safety of raas inhibitor therapy: a clinical and pharmacovigilant study
topic RS1-441 Pharmacy and materia medica
url http://eprints.usm.my/62705/
http://eprints.usm.my/62705/1/24%20Pages%20from%20MOHAMMAD%20ALI%20MOHAMMAD%20KHALEEL.pdf